von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study
about
Genetic Loci associated with C-reactive protein levels and risk of coronary heart diseasePotential role of ultrafine particles in associations between airborne particle mass and cardiovascular health.Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress?Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?Cardiovascular risk assessment in patients with diabetes.Diabetes is a proinflammatory state: a translational perspective.The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke.Human C-reactive protein and the metabolic syndrome.Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathyPrognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients.Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study.Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies.Endothelial dysfunction as a predictor of cardiovascular disease in type 1 diabetes.Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes TrialInflammatory Cytokine Profile Associated with Metabolic Syndrome in Adult Patients with Type 1 DiabetesEstimated Creatinine Clearance, Homocysteine and High Sensitivity-C-Reactive Protein Levels Determination for Early Prediction of Nephropathy and Atherosclerosis Risk In Type 2 Diabetic Patients.Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus.Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study.Serum Total Sialic Acid and Highly Sensitive C-reactive Protein: Prognostic Markers for the Diabetic Nephropathy.Effects of Synbiotics on Inflammatory Markers in Patients With Type 2 Diabetes Mellitus.ADAMTS13: a new link between thrombosis and inflammation.Endothelial dysfunction and microvascular complications in type 1 diabetes mellitus.Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications.The use of high-sensitivity assays for C-reactive protein in clinical practice.NALP3-Inflammasome-Related Gene Polymorphisms in Patients with Prehypertension and Coronary Atherosclerosis.Genetic predictors of depressive symptoms in cardiac patients.Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS)Risk Factors, Coronary Severity, Outcome and ABO Blood Group: A Large Chinese Han Cohort Study.Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study.Prognostic Importance of C-Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study.Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus.von Willebrand factor: at the crossroads of bleeding and thrombosis.The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.Alcohol and red wine consumption, but not fruit, vegetables, fish or dairy products, are associated with less endothelial dysfunction and less low-grade inflammation: the Hoorn Study.Work-family life courses and markers of stress and inflammation in mid-life: evidence from the National Child Development Study.Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes.Short-term effects of air pollution: a panel study of blood markers in patients with chronic pulmonary disease.Glycemic control modifies the association between microalbuminuria and c-reactive protein in Type 2 Diabetes Mellitus.High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.Endothelial activation markers in anemic non-dialysis chronic kidney disease patients.
P2860
Q24649709-188919EB-85CD-4319-8CF6-CE5E884D6C2BQ24815147-832788C7-52FB-4C45-9A58-2C65CB312007Q26851362-9143BEB9-09D5-425C-BB0F-4C327453385BQ33474334-49CE98A8-46C1-4105-8D25-2CEA40313E98Q33582582-89D780DC-A141-48B5-B35A-D79BF09FAD85Q33693974-2361F530-7507-4FE3-A501-9C9162EB64FCQ34054032-A53CEB6A-09F6-4EB9-96BC-3C0A540F32BEQ34066540-DCBAA25E-3B8F-4E00-9FAE-0DC5683C415DQ34388076-36A17ABB-E7A2-4BA7-A328-89CA7E4802FBQ34725081-4E52AEA1-1C2F-42E2-8C8A-8D68F4A422DCQ34969475-4A0B9EA6-5716-4988-8236-F73B328523B0Q35688195-57607D71-AF7A-4FB4-8162-9ED3ED81883FQ35691365-634DAB6C-2AB0-45B3-A31B-5A3DADAB0484Q35757048-7B965F32-66EF-4B32-9212-54EFDCB2E566Q35932408-423F9CEE-C148-4761-8DBF-8CEB44511FE0Q36079990-3755B0A1-7DF4-4E52-8AFF-836E50A54396Q36196407-999188F3-465C-41B9-8F1F-97020BB440DBQ36227082-EE4AEEEE-F417-407D-A26A-3B721147A3FCQ36671832-C278D397-513E-48F2-B3B9-1D546C2E08F0Q36717912-CBB8C870-AC72-4473-B7A6-24B65C8E3F08Q36853418-C21BCE63-9D56-44EE-9965-792D9D1F1B7AQ36854450-A30A03C3-8A46-46C8-8B4C-138C3929542AQ36951311-A9485792-9222-494C-A7CA-6DB608FA5103Q37090943-33239A23-ED95-4C83-BBF3-9FAB78FE8787Q37092859-FE284284-60E1-43F1-AA4F-8DA06E767C61Q37139308-D91DD0EC-3673-475B-BB20-B0ECC6866FBDQ37157478-A2F2DA06-5991-4148-9E56-87CDE84BE347Q37176137-515965EC-0372-4239-8BA0-140E1CC62F34Q37353655-5439F131-9AF5-4BC5-8600-9909A94E5FD6Q37556069-04ADD897-CCC4-4F5D-A525-C49353CD1645Q37685079-4BD1DA2F-0794-4DF3-8DB5-8E44578403BCQ38000162-051B3E87-D091-4EA2-80A4-6059EE891F97Q38716432-8A7190F8-7FAA-47AD-9FEA-EE2EA3ACB275Q40270866-83D900D7-3D0E-4424-A1AF-4C1F6D9C52B2Q40431102-59D7C6B9-8901-4942-8B35-F23FF6545A52Q41203311-8A026F72-DFEA-4E0F-9909-17CF34E67397Q41828146-C27426DB-0158-41F9-B71E-39C489399D11Q41838292-79CB0A9C-5726-457D-B7CD-21FEB7579208Q47610786-C85C03AA-9027-4087-87B5-4E9D5511FC2DQ53442889-9CDF5FCF-4C2D-464E-8BC2-A9D886B44EB1
P2860
von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study
description
im Dezember 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 1999
@uk
name
von Willebrand factor, C-react ...... etic subjects: the Hoorn Study
@en
von Willebrand factor, C-react ...... etic subjects: the Hoorn Study
@nl
type
label
von Willebrand factor, C-react ...... etic subjects: the Hoorn Study
@en
von Willebrand factor, C-react ...... etic subjects: the Hoorn Study
@nl
prefLabel
von Willebrand factor, C-react ...... etic subjects: the Hoorn Study
@en
von Willebrand factor, C-react ...... etic subjects: the Hoorn Study
@nl
P2093
P50
P1476
von Willebrand factor, C-react ...... etic subjects: the Hoorn Study
@en
P2093
C D Stehouwer
J S Yudkin
P J Kostense
V W van Hinsbergh
P304
P407
P577
1999-12-01T00:00:00Z